摘要
萘丁美酮是一种新型非酸性非甾体抗炎药。为了比较研究该药与阳性对照药萘普生对类风湿关节炎的疗效和安全性，我们组织全国三个中心对萘丁美酮和萘普生治疗类风湿关节炎进行了随机、双盲、多中心和平行性的Ⅱ期临床试验。结果表明：经４ｗｋ治疗后，萘丁美酮总有效率为６６．６７％，萘普生总有效率为５８．３３％，两者疗效接近。萘丁美酮的不良反应发生率为１１．６７％，萘普生的不良反应发生率为２３．３３％，差异显著。提示萘丁美酮治疗类风湿关节炎疗效明显，与萘普生疗效相近，但不良反应发生率明显低于萘普生。
To study the efficacy and safety of nabumetone(NAB)in patients with rheumatoid arthritis (RA), radomized,controlled, double-blind clinical trials of NAB versus naproxen (NAP)were performed in three hospital under organization of Base of Clinical Pharmacology,Anhui Medical University.The results indicated the total efficacy rates of NAB and NAP were 66.67% and 58.33% respectively after four weeks'treatment. The incidences of adverse effects were 11.67% and 23.33% respectively.These suggest the NAB had a similar efficacy with NAP in the treatment of patients with RA, but its adverse effects were significantly lower than that of NAP.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
1995年第1期7-10,共4页
The Chinese Journal of Clinical Pharmacology
